Robert F. Kennedy Jr. on fda: what the evidence says · JRE #2461
SUBJECT: FDA
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
During the Biden administration, They illegally move those to category 2, which says, do not formulate. It was illegal because they're not supposed to do that unless there's a safety signal, and they didn't have a safety signal.
What the evidence says 01 / RECORD
In late 2023, under the Biden administration, the FDA reclassified more than a dozen popular peptides (including BPC-157 and others, reportedly around 19 total) as Category 2 bulk drug substances, a designation that bars compounding pharmacies from preparing them. Reporting from STAT and PolitiFact confirms the move was explicitly framed as safety-motivated, citing concerns such as lack of clinical trial data and unproven safety in humans, contradicting the claim that no safety rationale existed. Critics, including compounding advocates, have disputed whether the specific statutory 'safety signal' threshold was clearly met for every peptide on the list, but no reporting found supports the claim that the reclassification was done without any stated safety basis. As HHS Secretary, Kennedy, who has said he personally uses peptides, has pushed to reverse the restriction and make peptides more accessible again. Restricting compounded access has been linked by industry advocates and some reporting to a gray/black market for imported peptides sold with 'research use only' disclaimers, though this dynamic is not established as a direct causal FDA policy failure by independent reporting.
Evidence sources 03 / EXHIBITS
Who Benefits
Kennedy has said he personally uses peptides and, as HHS Secretary, has pushed to end what he calls the 'war on peptides' and make them more accessible again, a direct policy benefit to the compounded-peptide industry and users like himself, though no direct financial stake (ownership, sales, endorsement deals) in a specific peptide company was found in reporting.